By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.

On May 23, New Horizon Health (6606.HK) and Prenetics Group Limited (NASDAQ: PRE, Prenetics for short) jointly announced a strategic cooperation to promote the listing of cancer early screening product ColoClear in Hong Kong and "going overseas" to Southeast Asia.

Hitachi High-Tech and Invivoscribe on Monday announced a partnership to combine their expertise and technologies to develop molecular diagnostics to diagnose cancer and monitor disease during treatment.

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy

C2i Genomics launches minimal residual disease test across Europe after clearing regulatory hurdles in the EU, UK, and Switzerland.

Liquid biopsy performed on serum samples taken from breast cancer patients can provide increasingly accurate information on cancer progression and enable earlier detection of cancer recurrence, a new study from the University of Eastern Finland and Kuopio University Hospital shows.

University of Notre Dame researchers have discovered another way tumor cells transfer genetic material to other cells in their microenvironment, causing cancer to spread.

Roche said on Friday that it has entered into a collaboration with Bristol Myers Squibb to develop and deploy two assays with new digital pathology algorithms for clinical trials.

Researchers at Queen Mary University of London have developed the world’s first PCR test for mouth cancer.

Burning Rock Biotech said on Tuesday that the National Medical Products Administration of China has approved its nine-gene sequencing assay, LungCure CDx, as a Class III medical device.